Total
0
Shares
Patrys (ASX:PAB) - - The Market Herald
Source: Shutterstock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • A new study featuring Patrys' (PAB) PAT-DX1 candidate demonstrates its ability to inhibit the growth of primary and secondary brain cancers
  • Data from the study highlights the drug's ability to selectively kill cancer cells by blocking their DNA damage repair systems
  • The treatment has also been found to extend the median survival rate for two different brain cancers
  • Findings from the study have been published in The Journal of Clinical Investigation—Insight
  • Patrys shares are up 7.32 per cent and trading at 4.4 cents at 12.13 pm AEST

A new study featuring Patrys' (PAD) PAT-DX1 candidate has demonstrated its ability to inhibit the growth of primary and secondary brain cancers.

Findings from the study have been published in The Journal of Clinical Investigation—Insight and highlight the drug's ability to selectively kill cancer cells by blocking their DNA damage repair systems.

More boradly, Patrys affirms the study provides data that indicates the potential for Patrys’ deoxymabs to provide new therapeutic options for brain cancer treatments.

The data was obtained from three different animal model studies. In which, human glioblastoma cells — an aggressive form of brain cancer — were implanted into the animal's brain tissue and subsequently treated with PAT-DX1.

The treatment was found to extend the median survival rate of two different glioblastoma models by 47 per cent and 25 per cent or 24 days versus 17 days and 73 days versus 58 days respectively.

Patrys Chief Executive Officer and Managing Director Dr. James Campbell said the company was on track for its fist PAT-DX1 human trials in the first half of 2022.

"Glioblastoma and TNBC brain metastatses are very difficult to treat, and the prognosis for patients with these cancers is generally poor," he said.

"This publication, in a highly-regarded, peer-reviewed journal is further validation of the pioneering position that Patrys and its collaborators at Yale School of Medicine have established with its deoxymab platform."

Patrys shares were up 7.32 per cent and trading at 4.4 cents at 12.13 pm AEST.

PAB by the numbers
More From The Market Herald
BARD1 Life Sciences (ASX:BD1) - CEO, Leearne Hinch - The Market Herald

" BARD1 Life Sciences (ASX:BD1) updates the market on Q4

BARD1 Life Sciences (BD1) has reported advances across its sales, business development and commercialisation activities over the June quarter.
Incannex Healthcare (ASX:IHL) - Chief Medical Officer, Dr Sud Agarwal (centre) - The Market Herald

" Incannex Healthcare (ASX:IHL) has a progressive fourth quarter

Incannex Healthcare (IHL) has spent the fourth quarter progressing its cannabinoid pharmaceutical products and psychedelic medicine therapies.
Prescient Therapeutics (PTX) - CEO & Managing Director, Steven Yatomi Clarke - The Market Herald

" Prescient Therapeutics (ASX:PTX) advances clinical studies in June quarter

Prescient Therapeutics (PTX) has summarised its operations and cashflow for the June quarter.
Mesoblast (ASX:MSB) - Managing Director & CEO, Silviu Itescu - The Market Herald

" Mesoblast (ASX:MSB) trades lower following June quarterly report

Drug developer Mesoblast (MSB) is trading red following the release of its latest quarterly financial report.